QuantHealth has raised $45 million in a Series B funding round led by Qumra Capital to expand its AI-driven clinical trial simulation platform and accelerate adoption of simulation-first drug development.

The financing follows an eightfold increase in sales during 2025 and will support research and development, product development and commercial expansion.

The round also includes investment from Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund, Bertelsmann Healthcare Investments, GC Ventures, NewHealth Ventures, Shoni Health Ventures and Esplanade Ventures among others.

QuantHealth plans to use the funding to develop new AI models, expand its datasets and therapeutic coverage and increase the scientific validation of its technology.

The company also intends to grow its workforce and expand its product offering across the clinical and commercial development lifecycle, including clinical trial design and go-to-market positioning.

AI simulation aims to improve clinical trial decisions

QuantHealth’s platform is designed to allow pharmaceutical and biotechnology companies to simulate clinical trials before patients are enrolled.

The company said its approach is intended to help drug developers assess and optimise trial designs using AI-powered simulations rather than relying solely on historical benchmarks and assumptions.

QuantHealth has simulated more than 600 clinical trials across 30 indications and said its models have achieved up to 90% predictive accuracy.

The company plans to expand its coverage to more than 40 indications, with a focus on areas including oncology, cardiometabolic disease and inflammation.

“Today, clinical development decisions are still largely made through real-world iteration—running trials, waiting for results, and adjusting at significant cost and risk. We’re fundamentally changing that model,” said Orr Inbar, CEO and co-founder of QuantHealth.

“With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital. This funding allows us to scale that approach, making simulation a standard step in development and fundamentally improving how drugs are brought to market.”

Clinical trials remain one of the most expensive and uncertain stages of drug development, with QuantHealth citing industry estimates that more than 90% of drugs entering clinical development ultimately fail.

The company said its technology is intended to help pharmaceutical and biotechnology companies make decisions around trial design earlier in development, potentially reducing the risks associated with unsuccessful or poorly designed studies.

QuantHealth targets wider use of AI in drug development

The new funding will also support expansion of QuantHealth’s technology across the wider drug development lifecycle.

The company said it plans to develop products that cover clinical development through to commercial decision-making, while focusing on demonstrating measurable impact for customers.

Reut Yehuda Golan, partner at Qumra Capital, said: “AI has already transformed drug discovery, and clinical trials are the next frontier. It’s a market in which hundreds of billions of dollars are spent annually on clinical trials, and one that is ripe for a smarter, more efficient approach.”

Golan added that QuantHealth’s technology had reached a point where the company believes it can expand its role in AI-enabled clinical development.

The investment also builds on an existing relationship with Sanofi Ventures, which participated in the funding round after previously investing in QuantHealth.

“As one of QuantHealth’s earliest investors, we have had the opportunity to watch the company help define an emerging category at the intersection of AI and clinical development,” said Cris De Luca, partner at Sanofi Ventures.

“As the pharmaceutical industry increasingly looks to leverage AI to improve decision-making across the development lifecycle, simulation technologies are becoming an important part of the drug development toolkit.”

QuantHealth said it has worked with 12 of the world’s top 20 pharmaceutical companies. The company will use the new funding to increase adoption of its simulation technology and expand its presence across drug development.

The Series B brings QuantHealth’s total funding to approximately $70M, according to the company, following its previous financing and strategic investment from Sanofi Ventures.